Octreotide Therapy

Primary FDA-Approved Indications

The National Comprehensive Cancer Network recommends initiating octreotide immediately in patients with metastatic carcinoid tumors presenting with carcinoid syndrome, with a mean daily dosage of 300 mcg, and transitioning to octreotide LAR 20-30 mg intramuscularly every 4 weeks once symptoms are controlled 1, 2
For patients with clinically significant tumor burden from metastatic carcinoid tumors, the National Comprehensive Cancer Network recommends initiating octreotide LAR for tumor growth control, based on the PROMID trial showing median time to tumor progression of 14.3 months with octreotide LAR versus 6 months with placebo 1, 2
The National Comprehensive Cancer Network suggests that patients with clinically significant progression of metastatic carcinoid tumors should be started on octreotide if not already receiving it, with short-acting octreotide added to LAR for breakthrough symptoms 1, 2

For acute variceal bleeding, the Praxis Medical Insights guideline recommends giving octreotide as a 50 mcg IV bolus followed by continuous infusion at 50 μg/hour, continuing for 2-5 days until hemodynamic stability is achieved 3
For patients with carcinoid syndrome undergoing procedures, the Praxis Medical Insights guideline recommends prophylactic octreotide by IV infusion at 50 μg/hour starting 12 hours before and continuing 24-48 hours after the procedure, with cardiology consultation and echocardiogram before major surgery 3, 1, 2
For severe or loperamide-refractory chemotherapy-induced diarrhea, the Praxis Medical Insights guideline recommends giving continuous IV infusion at 25-50 μg/hour until diarrhea resolves, with higher doses (up to 500 μg three times daily) potentially more effective than lower doses 3

Patients with 5-HIAA levels ≥300 mcmol over 24 hours and ≥3 flushing episodes per day are at higher risk for carcinoid heart disease, according to the National Comprehensive Cancer Network 1, 2
The Praxis Medical Insights guideline advises against discontinuing octreotide prematurely in variceal bleeding before achieving hemodynamic stability, and against using inadequate dosing for severe secretory diarrhea in carcinoid syndrome or VIPomas 3
The National Comprehensive Cancer Network recommends remembering that octreotide LAR requires 10-14 days to reach therapeutic levels, and bridging with short-acting formulation for immediate symptom control 1, 2